ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan

• Loan provides additional financing to the € 36m non-dilutive funding granted by Bpifrance in May 2020
• Abivax’s operations and ongoing clinical study programs fully financed until early 2021
• Further non-dilutive financing opportunities are being evaluated

PARIS, FRANCE / ACCESSWIRE / June 15, 2020 / Abivax SA (Euronext Paris:FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that it has received € 5m in non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE – Prêts Garantis par l’Etat).

This € 5m loan is structured with an initial maturity of 12 months at a 0.25% interest rate and an option for up to 5 years extension. This non-dilutive loan extends Abivax’s cash runway into early 2021.

Prof. Hartmut Ehrlich, M.D., CEO of Abivax, said: “The financing granted by Bpifrance, now complemented by Société Générale, allows Abivax to maintain the rapid development pace of our ongoing and planned clinical study programs. Patient recruitment is progressing well and according to our expectations for our clinical trials with ABX464, i.e. Phase 2b in ulcerative colitis and Phase 2a in rheumatoid arthritis, as well as for the Phase 1/2 trial with ABX196 in hepatocellular carcinoma. We will soon be treating the first patient in the COVID-19 study with ABX464, which will be conducted in Europe as well as Brazil and possibly additional countries in Latin America, where the pandemic still has not reached its peak. In parallel, Abivax is already preparing for potential marketing authorizations and global commercialization of ABX464 for the treatment of high-risk COVID-19 patients.”

Didier Blondel, Chief Financial Officer of Abivax, added: “Beyond the € 36m funding from Bpifrance, this € 5m funding from Société Générale is extending our cash resources until early 2021. In the short-term, to be able to fully execute on its corporate objectives and to maintain its current development plans and timelines, Abivax is planning to secure at least € 30m additional financing. We remain in regular discussion with a number of stakeholders to evaluate these additional financing opportunities, and we continue to focus on non-dilutive options.”

About Abivax
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84

Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates with respect to certain of the Company’s programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

SOURCE: ABIVAX

View source version on accesswire.com:
https://www.accesswire.com/593934/ABIVAX-Abivax-receives-5m-non-dilutive-financing-from-Socit-Gnrale-as-State-Guaranteed-Loan